Facial psoriasis is a chronic skin condition in which there are one or more, persistent, thickened, red and dry patches on the face.
Psoriasis is a common chronic inflammatory skin disease that may affect any skin site. Facial involvement occurs at some time in about half those affected by psoriasis. Although it is usually mild, facial psoriasis is occasionally very extensive involving the hairline, forehead, neck, ears and facial skin.
It is extremely rare to have psoriasis occurring solely on the face. Most patients also have scalp psoriasis and they may also have moderate to severe psoriasis at other sites.
Patients with facial psoriasis often suffer from psychosocial problems due to the presence of unsightly red, scalyplaques on highly visible areas.
Facial involvement presents as a therapeutic challenge because facial skin is thin, sensitive and more complicated to treat.
What are the clinical features of facial psoriasis?
Facial psoriasis has various clinical presentations. There are three main subtypes:
Hairline psoriasis
Sebo-psoriasis
True facial psoriasis.
Hairline psoriasis
An extension of scalp psoriasis beyond the hairline onto facial skin
Bright red, thickened plaques with variable white scale
Facial psoriasis
Facial psoriasis
Facial psoriasis
Sebo-psoriasis
Patchy involvement of the hairline
Often affects the eyelids, eyebrows, nasolabial folds and beard area
Salmon-pink, thin plaques with bran-like scale
Usually associated with diffuse or patchy scalp psoriasis
Psoriasis may or may not be present at other sites
Facial psoriasis
Eyelid psoriasis
Facial psoriasis
True facial psoriasis
Sharply demarcated, red, scaly plaques
May affect any part of the face
Plaques tend to be symmetrical
Associated with psoriasis at other sites including ears, genitals, scalp, elbows, knees, and trunk
Soreness and skin sensitivity, which are usually mild
What causes facial psoriasis?
The causes of facial psoriasis are the same as for psoriasis in general. Psoriasis is associated with inappropriate activation of the immune system resulting in inflammation and increased proliferation of skin cells. There is a geneticpredisposition, but environmental influences are important, including stress, infection, injuries and certain medications.
Facial psoriasis may also be aggravated by:
Ultraviolet radiation — some patients have photosensitivity where the psoriasis is aggravated by exposure to the sun
There is no cure for facial psoriasis, but satisfactory control of the disease is possible for most patients using topical therapy. General skin care may include:
Gentle non-soap cleansers
Moisturisers
Sunscreens, if required.
Corticosteroid creams
Mild or moderate strength topical steroids reduce inflammation and relieve itching. Side effects of corticosteroids restrict the potency and duration of use on the face. These include:
Risk of glaucoma and cataracts from long-term use of potent steroid creams around eyelids.
Hydrocortisone is generally safe. More potent topical steroids are best used on the face for only a few days each month.
Topical calcineurin inhibitors
The topical calcineurin inhibitorspimecrolimuscream and tacrolimusointment may be prescribed off-label for facial psoriasis and can be very effective. They are particularly useful on eyelid skin. In New Zealand, these preparations are not currently subsidised by PHARMAC (February 2019).
Other topical preparations
Salicylic acid is a descaling agent found in many over-the-counter creams.
The vitamin D analogues, calcipotriol/calcipotriene and calcitriol tend to irritate facial skin. Cream or gelformulations may be tolerated, especially in combination with topical steroids.
Coal tar creams may cause staining and irritation.
The topical phosphodiesterase-4 topical inhibitor, roflumilast, is approved for the treatment of plaque psoriasis (2022).
Off-label use of the phosphodiesterase-4 topical inhibitor crisaborole has been shown to be effective for facial psoriasis.
Phototherapy
Sun exposure or prescribed phototherapy is often helpful for facial psoriasis.
Severe facial psoriasis sometimes warrants treatment with tablets or injections such as methotrexate, ciclosporin, acitretin or biologic agents. Patients should be under the care of an experienced dermatologist and should be carefully monitored.
What is the prognosis?
Facial psoriasis tends to persist, although its severity may vary with season, stress and other factors. It may be a marker of more severe disease with early-onset, long duration and more extensive plaques.
References
Canpolat F, Cemil BC, Eskioglu F, Akis HK. Is facial involvement a sign of severe psoriasis? Eur J Dermatol. 2008 Mar-Apr;18(2):169-71. PubMed
Jacobi A, Braeutigam M, Mahler V, Schultz E, Hertl M. Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study. Dermatology: 216(2):133–6. PubMed
Kroft EBM., Erceg A., Maimets K., Vissers W., Van der Valk PGM., Van de Kerkhof PCM. 2005. Tacrolimus ointment for the treatment of severe facial plaque psoriasis. J Eur Acad Dermatol Venereol. 2005 Mar;19(2):249–51. PubMed
Hashim PW, Chima M, Kim HJ, et al. Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: a double-blind, randomized, vehicle-controlled trial. J Am Acad Dermatol. 2020;82(2):360-365. doi: 10.1016/j.jaad.2019.06. PubMed